Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study

Ohta,Shoichiro; Yasuno,Nobuhiro; Inomoto,Yuki; Matsuda,Kaori; Nakagawa,Yoshihiko; Sasagawa,Isoji; Tanaka,Masahiko

doi:10.3892/etm.2013.1384

2014-January Volume 7 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-January Volume 7 Issue 1

Full Size Image

Article

Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study

Authors:
- Shoichiro Ohta
- Nobuhiro Yasuno
- Yuki Inomoto
- Kaori Matsuda
- Yoshihiko Nakagawa
- Isoji Sasagawa
- Masahiko Tanaka
View Affiliations / Copyright

Affiliations: Department of Urology and Hemodialysis, Kan‑Etsu Hospital, Tsurugashima, Saitama, Japan, Department of Pharmacy, Kan‑Etsu Hospital, Tsurugashima, Saitama, Japan, Minami‑Cho Clinic, Sakado, Saitama, Japan, Department of Urology, Yamagata Tokushukai Hospital, Yamagata, Japan, Department of Rheumatology, Kan‑Etsu Hospital, Tsurugashima, Saitama, Japan
Pages: 27-30
|
Published online on: November 6, 2013

https://doi.org/10.3892/etm.2013.1384
Expand metrics +

Abstract

Several clinically approved recombinant erythropoietin (rEPO) preparations, such as epoetin‑β, epoetin‑δ and the epoetin‑α derivative, darbepoetin‑α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin‑κ, which is biosimilar to epoetin‑α, was clinically approved. Epoetin‑κ is a biopharmaceutical product that is based on serum‑free media following master cell bank preparation. The present study analyzes the results obtained during a six‑month observation period, in which the administration of epoetin‑β was switched to that of epoetin‑κ. In a cohort of patients receiving chronic dialysis, who were clinically in a state of relative calm and were in control of their renal anemia, it was possible to sustain good control of the anemia by reducing the frequency of the epoetin‑β administration from the conventional and empirically determined three times a week to twice a week, and further to once a week. Furthermore, the good control was maintained upon changing from the administration of epoetin‑β to that of epoetin‑κ. Moreover, three months subsequent to this switch, the degree of instability observed among the patients had decreased. Despite the fact that the situation following the changeover requires further investigation, it may be concluded that the results obtained in this study are indicative of the clinical equivalence and efficacy of epoetin‑κ.

View Figures

View References

1	Pisoni RL, Bragg-Gresham JL, Young EW, et al: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 44:94–111. 2004. View Article : Google Scholar : PubMed/NCBI
2	Hirai T, Sugiya N, Nakashima A, Takasugi N and Yorioka N: Switching from epoetin alpha to darbepoietin alpha in Japanese hemodialysis patients: dose conversion ratio. Nephron Clin Pract. 111:c81–c86. 2009. View Article : Google Scholar : PubMed/NCBI
3	Okano M, Sato M, Kaneko E and Kageyama S: Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application. Drug Test Analysis. 3:798–805. 2011. View Article : Google Scholar
4	Brinks V, Hawe A, Basmeleh MA, et al: Quality of original and biosimilar epoetin products. Pharm Res. 28:386–393. 2011. View Article : Google Scholar : PubMed/NCBI
5	Haag-Weber M, Vetter A and Thyroff-Friesinger U; INJ-Study Group. Therapeutic equivalence, lomg-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 72:380–390. 2009.PubMed/NCBI
6	European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - guidance on similar medicinal products containing recombinant erythropoietins. EMEA/CHMP/945626/2005 Corr. 2006.
7	Park SS, Park J, Ko J, et al: Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci. 98:1688–1699. 2009. View Article : Google Scholar : PubMed/NCBI
8	Jelkmann W: Biosimilar epoetins and other ‘follow-on’ biologics: update on the European experiences. Am J Hematol. 85:771–780. 2010.
9	KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 50:471–530. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ebben JP, Glibertson DT, Foley RN and Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Nephrol. 1:1205–1210. 2006. View Article : Google Scholar : PubMed/NCBI
11	Schellekens H: How similar do ‘biosimilars’ need to be? Nat Biotechnol. 22:1357–1359. 2004.
12	Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 355:2085–2098. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kissei Pharmaceutical Co; Interview Form, Epoetin-Alpha Bs injection. 2010.
14	Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:584–590. 1998. View Article : Google Scholar : PubMed/NCBI
15	Fishbane S and Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 68:1337–1343. 2005. View Article : Google Scholar : PubMed/NCBI